TETs SumUP: Summer Update on Thymic Epithelial Tumors

BACKGROUND AND RATIONALE Thymic epithelial tumors (TETs) are rare malignancies, with a cumulative incidence of 1.3-3.2 cases/1,000,000, that is about 230 new cases/year in Italy. The diagnosis and treatment of TETs require the presence of a multidisciplinary team including at least a Medical Oncologist, a Thoracic Surgeon, and a Radiation Oncologist. The collaboration of a Neurologist and an Immunologist is also useful, due to the possible association with TETs of several paraneoplastic syndromes. Furthermore, the rarity of TETs hinders the conduction of clinical trials and translational research, so that the generation of high-level scientific evidence is hard. In the end, the complexity and extreme rarity of TETs often imply unequal standards of care and a lack of shared guidelines. This worsens the problem of difficult access to high-quality care, which is a common concern for TET patients. All these considerations have led Fondazione IRCCS Istituto Nazionale dei Tumori (INT), which is a national and international reference Institution for TETs, to be promoter and co-founder of TYME (ThyYmic MalignasiEs) network in 2014. TYME aims to promote collaboration among the Centers with specific multidisciplinary expertise on TETs. TYME objectives include: improvement and standardization of therapeutic standards; sharing of treatment principles and guidelines; support to research at both national and international levels. Since 2017, INT has also been a member of the European reference network for rare thoracic cancers (EURACAN-ERNs). ERNs aim to create collaborations among European excellence Centers for sharing of knowledge and coordination of care about rare diseases. The purpose of this international conference is to share knowledge on crucial topics related to the diagnosis and treatment of TET patients. It also aims to promote discussion among paramount speakers of controversial clinical cases. This approach will further clarify the need for patients’ referral to Centers with high expertise on the disease and a dedicated multidisciplinary team.